12 unchanged sentences
On February 27, 2020, the Federal Circuit vacated the ‘127 IPR decision and remanded it back to the PTAB for rehearing, where it is presently being held in abeyance until the Supreme Court acts on a petition for writ of certiorari filed July 23, 2020 in a different case.
+Added: On October 13, 2020, the Supreme Court granted certiorari in United States v.
+Added: which was the basis of the Federal Circuit’s remand in the ‘127 IPR.
On November 27, 2019, Moderna and Arbutus both appealed the ‘435 IPR decision.
1 unchanged sentence
Arbutus’ opening and responsive brief was provided on July 27, 2020.
+Added: Moderna filed its reply and responsive brief on October 5, 2020.
On January 9, 2019, Moderna filed an additional petition requesting Inter Partes Review of Arbutus United States Patent 8,058,069 (“’069 patent”).
1 unchanged sentence
On July 23, 2020, the PTAB rendered its decision on the ‘069 patent, upholding all claims as valid.
+Added: On September 23, 2020, Moderna appealed the ‘069 IPR decision.
Moderna and Merck European Oppositions
5 unchanged sentences
Merck filed its notice of appeal on February 24, 2020 and Moderna on February 27, 2020.
−Removed: Arbutus’ response is due on September 8, 2020.
+Added: Arbutus’ response was filed on September 8, 2020.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.